European Commission approved Illumina's plan to divest Grail due to antitrust concerns.
The European Commission approved Illumina's plan to divest cancer test maker Grail, which the companies were ordered to unwind due to antitrust concerns. Illumina completed the acquisition of Grail in 2021 but faced scrutiny from regulators. The EU regulators have now given their approval for Illumina to proceed with the divestment, either through a capital markets transaction or a trade sale.
April 12, 2024
8 Articles